Immune cell therapy with a PD-1 blocker for young people with medulloblastoma that came back
Official title: Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether immune cell treatment plus a PD-1 blocker is safe for children and young adults whose medulloblastoma has come back or is growing.
Read our full plain-language summary
What the trial team says
This is a pilot study in a small number of children and young adults with suspected recurrent/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.
Key facts
- Registry number
- NCT06514898
- Stage of testing
- Phase 1
- Conditions studied
- Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Where it is running
This trial lists 2 sites.
-
District of Columbia
- Children's National Hospital (Washington D.C.)
-
Florida
- University of Florida Health (Gainesville)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.